The review, led by Santanu Misra of Sungkyunkwan University and Chiho Yoon of Pohang University of Science and Technology, together with colleagues including Chulhong Kim and Byullee Park, takes stock of deep learning-based virtual histological staining, a technique in which neural networks learn to translate label-free images of unstained tissue—or images stained with one dye—into photorealistic syntheses of stains that were never applied. The authors frame the technology as having already left the proof-of-concept stage, with demonstrations spanning quantitative phase microscopy, autofluorescence imaging, photoacoustic microscopy, optical coherence tomography, Raman and infrared spectroscopy, and even in vivo imaging of human skin. But they warn that inconsistent data handling, model design, and evaluation practices are now actively slowing its march into the clinic.

The technical core of virtual staining is a data-driven image-to-image transformation. In the label-free setting, a network is trained on pairs of images: a tissue region imaged without dyes, and the same region after chemical staining. The network learns the mapping between intrinsic optical signals—autofluorescence from cellular metabolites and structural proteins, phase shifts from refractive index variations, or endogenous absorption measured acoustically—and the characteristic color and contrast patterns of hematoxylin and eosin, Masson’s trichrome, or immunohistochemical markers. Once trained, the model can generate stain-like contrast directly from raw, unstained images, in some cases within seconds. In the stain-to-stain setting, the model instead converts one existing stain into another, allowing a laboratory to extract additional molecular or diagnostic information from a single stained section without cutting and processing more tissue.

The lineage of the field traces back to landmark demonstrations such as PhaseStain, which digitally stained label-free quantitative phase images in 2019, and virtual H&E staining of tissue autofluorescence published the same year in Nature Biomedical Engineering. Since then, the review documents an accelerating proliferation: virtual staining of biopsy-free in vivo skin, of human carotid atherosclerotic tissue, of autopsy material, of amyloid deposits via birefringence imaging, and of glioma tissue from hyperspectral images. Diffusion models, which generate images through iterative denoising, have recently joined generative adversarial networks as workhorse architectures, with pixel super-resolution virtual staining and pathology-aware Schrödinger bridge approaches pushing both fidelity and training efficiency. Transformer-based backbones have been adapted to capture the long-range tissue context that convolutional networks can miss.

The prize is substantial. Chemical staining and the turnaround time it imposes are bottlenecks in surgical pathology, particularly during operations when frozen sections must be prepared, stained, and read in minutes. Label-free virtual staining could eliminate that delay entirely: photoacoustic-based systems have already demonstrated label-free intraoperative histology of bone tissue and rapid cancer diagnosis at subcellular resolution, allowing surgeons to receive histology-grade feedback without waiting for a cryostat. Because the tissue is never chemically processed or destroyed, virtual staining also preserves material for molecular testing, enables repeated virtual stains from a single section, and opens the door to stains that are impractical or impossible to perform chemically, such as virtual multiplexed immunostaining for assessing vascular invasion in cancer.

Yet the review’s central message is cautionary. The authors find that studies vary enormously in how imaging data are acquired, how tissues are curated, how image pairs are registered and preprocessed, how networks are configured, and—most consequentially—how results are evaluated. Because deep networks learn statistical correlations rather than physical laws, a model trained on autofluorescence images from one microscope, one tissue type, or one institution may fail silently when applied elsewhere, a problem known as domain shift. The review highlights the pathological extremes of this risk: hallucination, in which a generative network invents plausible-looking structures that do not exist in the underlying tissue. If a hallucinated morphological feature changes a diagnosis, the consequences could be severe, and recent work on scalable hallucination detection frameworks underscores how seriously the field now treats this failure mode.

To address the reproducibility gap, the authors propose a standardization blueprint that spans the entire pipeline: modality-specific data construction, model design, handling of domain shift, evaluation strategy, and safety assessment. A key deliverable is a minimum reporting checklist, analogous in spirit to the CLAIM, TRIPOD+AI, CONSORT-AI, and SPIRIT-AI guidelines that transformed reporting standards in medical imaging and clinical AI. The checklist would require researchers to disclose their datasets, imaging protocols, preprocessing steps, training configurations, and evaluation settings in a consistent format, enabling fair cross-study comparison and reproducible benchmarking. Without such disclosure, the authors argue, claims that one virtual staining system outperforms another are essentially unverifiable.

Evaluation itself receives pointed criticism. Common image-similarity metrics such as peak signal-to-noise ratio and structural similarity index, along with perceptual measures derived from deep features and distributional metrics like FID and MMD, reward statistical closeness to real stained images but do not guarantee that diagnostic content is preserved. A virtually stained image can score well on every pixel-level metric while subtly distorting nuclear morphology or inventing mitotic figures. The review calls for pathology-aware evaluation metrics, built around diagnostically relevant structures, and for expert reader studies in which pathologists assess whether virtual slides support the same interpretations as their chemical counterparts—an approach already tested in clinical-grade validation of an autofluorescence virtual staining system for prostate cancer.

The question of clinical translation is where the review is most deliberately sobering. The authors situate virtual staining within real pathology workflows, complete with whole-slide imaging, digital pathology infrastructure, and regulatory oversight, and conclude that full replacement of chemical staining is not yet routine—and should not be presented as imminent. Regulatory frameworks for AI-based diagnostic tools remain in flux, and the evidence base, while growing rapidly, still contains gaps in multicenter validation, long-term performance monitoring, and clear accountability when a virtual slide and a chemically stained slide disagree. The authors emphasize that near-term adoption is most realistic in well-defined niches: intraoperative consultation, rapid assessment where tissue is scarce, research settings requiring multiplexed stains, and adjunctive second reads rather than autonomous diagnosis.

That measured framing distinguishes the review from much of the celebratory literature. The field’s trajectory is undeniable: what began as a laboratory curiosity a decade ago now spans organ systems, imaging modalities, and stain types, with foundation models for computational pathology processing more than a hundred clinical-grade tasks. But the authors’ blueprint makes clear that the next phase of progress will be won not by bigger networks or flashier generative architectures, but by the unglamorous work of consistent reporting, rigorous benchmarking, hallucination safeguards, and regulatory engagement. If the community adopts these standards, the vision that animates the field—histology-grade images of living, unstained tissue, produced in seconds at the bedside or in the operating room—moves from a compelling demonstration to a defensible clinical tool. Until then, the dyes stay in the dish, and the burden of proof stays with the algorithms.

The multidisciplinary team behind this initiative comprises veterinary pathologists, machine learning experts, and experienced journal editors, showcasing a collective commitment to improving the standards of reporting in research that leverages AI technologies. The checklist meticulously outlines essential methodological components that authors should incorporate into their manuscripts, ensuring that all relevant aspects of the research process are transparent and easily accessible. By emphasizing the importance of detailed reporting, the authors aim to mitigate potential biases that could compromise research validity.

Among the key elements highlighted in the checklist are crucial details surrounding dataset creation, model training, and performance evaluation. These components are essential for understanding how AI systems operate and how their outcomes can be interpreted within the context of veterinary pathology. Furthermore, the interaction between researchers and the AI systems utilized is also a focal point, as this relationship can significantly influence the results reported in the literature. By adhering to these guidelines, researchers can achieve higher standards of clarity and consistency in their work.

In their writing, the authors stress that transparent reporting is not merely a procedural formality; it is a fundamental element for ensuring the reproducibility of research outcomes. As AI tools advance and are deployed more regularly in pathological analyses, the absence of clear methodologies can result in significant hurdles when researchers attempt to replicate findings. The importance of accessible supporting data, including training datasets and source code, cannot be overstated, as such resources are vital for external validation and broader application within the field.

The ramifications of withstanding rigorous scientific scrutiny through transparent reporting extend beyond academia; they pave the way for the practical translation of AI tools into everyday pathology workflows. This transition from experimental applications to routine practices hinges on the confidence that stakeholders—including clinicians and researchers—must feel about the reliability of AI findings. Thus, the checklist serves as an invaluable resource not only for authors but for reviewers and editors involved in the publication process.

By establishing a common framework for reporting AI-based studies, this checklist also helps to cultivate a culture of accountability and diligence within the research community. In an era where misinterpretations and erroneous conclusions can escalate quickly, the initiative encourages authors to invest the necessary effort to ensure that their methodologies are thoroughly documented and validated. This dedication to methodological transparency contributes to the integrity of scientific research, ultimately benefiting not only scientists, but also the animals and patients receiving care based on these findings.

The forthcoming special issue of Veterinary Pathology dedicated to AI further emphasizes the journal’s commitment to remaining at the forefront of scientific dialogue surrounding this rapidly evolving technology. This space will provide researchers with an opportunity to showcase their work while adhering to high standards of reporting, thus increasing the utility and credibility of their contributions to the field. The editors anticipate that the new guidelines will catalyze a meaningful shift in how AI-enabled research is conducted and reported.

In summary, the checklist put forth by this interdisciplinary team embodies a commitment to excellence in reporting and transparency in AI-based studies. As the veterinary pathology community embraces these transformative tools, the call for diligent reporting becomes ever more pertinent. Equipped with clear guidelines, researchers are better positioned to contribute meaningful insights to the field, reinforcing a foundation of trust and collaboration that will ultimately advance veterinary medicine. The potential benefits of integrating AI into pathology not only hold promise for enhanced diagnostic capabilities but also for improving patient outcomes through informed and reliable research.

Adopting these reporting standards is expected to serve as a beacon for future research projects, igniting interest and engagement among scholars dedicated to veterinary advancements. By promoting trust and collaboration through standardized reporting practices, we can hope for a future where the benefits of artificial intelligence in veterinary pathology are fully realized—benefits that extend beyond research institutions to impact clinical practices and enhance animal care globally.

As the veterinary community continues to evolve in the digital age, this checklist serves as a crucial mechanism for navigating the complexities associated with AI integration in pathology. Encouraging researchers to embrace transparency and rigor in their methodologies will lead to a richer, more productive dialogue around AI, fostering innovation that is securely grounded in reproducible scientific evidence.

In conclusion, the authors of the article published in Veterinary Pathology have not merely created a checklist; they have established a vital tool for ensuring that the advancements of AI are harnessed in a responsible and scientifically rigorous way. By committing to high-quality reporting, the veterinary pathology community stands to gain immensely, enabling the widespread adoption of AI tools that can enhance both research and clinical practice. The future of veterinary science, significantly influenced by artificial intelligence, is bright with this new emphasis on transparency and reproducibility at the forefront.

Subject of Research: Animal tissue samples
Article Title: Reporting guidelines for manuscripts that use artificial intelligence–based
News Publication Date: 2-Aug-2025
Web References: DOI Link
References: None provided
Image Credits: None provided

Keywords

Veterinary medicine, Artificial intelligence, Machine learning, Pathology, Animal science

Traditional prostate cancer diagnostics rely heavily on pathologists’ ability to interpret tissue biopsies under the microscope, a process that, despite its rigor, is subject to human limitations. The study, spearheaded by Carolina Wählby, Professor of Quantitative Microscopy at Uppsala University’s Department of Information Technology and SciLifeLab, demonstrates that AI can augment and surpass the sensitivity of experienced pathologists. By meticulously analyzing thousands of small regions within biopsy images, the AI algorithm was trained to detect complex and nuanced tissue patterns indicative of oncogenic transformation long before they become visually obvious.

One of the study’s most striking revelations is that more than eighty percent of men whose prostate biopsies were initially deemed healthy by expert pathologists showed subtle yet diagnostically relevant changes when analyzed by AI. These men were part of a cohort of 232 individuals who had been followed longitudinally, with half developing clinically aggressive prostate cancer within two and a half years, while the others remained cancer-free for at least eight years. This longitudinal aspect provides compelling evidence that the morphological cues identified by AI are not random artifacts but genuine precursors to malignant progression.

The technical approach embraced in this research leverages advanced imaging analysis on digitized histological slides. Unlike conventional methods that examine biopsies mostly as entire global samples, the AI systematically evaluates the tissue in small, interrelated segments, honing in on subtle glandular and stromal abnormalities. This granular level of inspection enables the detection of microenvironmental changes—such as alterations in gland architecture and surrounding connective tissue—that have been associated with early tumorigenesis but remain below the resolution of standard diagnostic criteria.

Building the AI model required a novel training strategy due to the inherent challenge of having only negative-labeled samples at baseline. The researchers circumvented this by adopting a weakly supervised learning framework, inferring that biopsy specimens from patients who later developed prostate cancer must harbor microscopic clues. Through this clever methodological innovation, the algorithm gradually learned to distinguish between benign and potentially malignant tissue patterns, despite the absence of explicit annotations marking the exact location of cancerous changes at the initial biopsy.

Furthermore, when the algorithm’s findings were interrogated, it highlighted tissue abnormalities consistently located around the prostate glandular regions, a discovery paralleling insights from prior molecular and morphological studies. These areas showed modifications that might precede cellular atypia or invasive carcinoma, including subtle variations in gland shape, epithelial-stromal interactions, and extracellular matrix remodeling. Such detailed tissue phenotyping through AI heralds a new era in precision pathology, where the microenvironmental context is integrated into cancer risk assessment.

The clinical significance of this study cannot be overstated. Currently, men with negative biopsy results often face uncertainty regarding their cancer risk and appropriate follow-up intervals. The AI-powered diagnostic tool offers a quantitative and objective measure to stratify patients according to their true risk profile, enabling earlier interventions and personalized monitoring schedules. By discerning which individuals are most likely to harbor occult neoplastic changes, the health care system can optimize resources and improve patient outcomes through timely therapeutic strategies.

Importantly, the multidisciplinary collaboration between Uppsala University and Umeå University facilitated the assembly of a robust and diverse dataset of tissue samples, enhancing the generalizability of the AI model. Data transparency and accessibility were prioritized, as the imaging datasets and analytical workflows have been made openly available to propel further research and refinement in this promising domain. Open science practices like these are integral to accelerating innovations bridging computer science and pathology.

While the promise of AI in medical diagnostics has been widely recognized, this study marks a concrete demonstration of its ability to detect molecularly silent yet morphologically indicative changes within ostensibly normal tissues. It paves the way for integrating AI as a complementary diagnostic modality alongside pathologists, aiming to reduce missed diagnoses and improve the predictive power of histopathological evaluations. The findings invite a reevaluation of diagnostic thresholds and call for clinical trials to validate AI-driven decision-making frameworks in routine prostate cancer screening.

Carolina Wählby and her team emphasize that their work is a stepping stone toward deploying AI tools that fundamentally rethink cancer detection—not by replacing human expertise, but by extending it. They advocate for a future where routine biopsies undergo dual scrutiny: traditional pathological examination followed by AI-powered imaging analysis, thereby drastically reducing the window in which aggressive prostate cancers remain undetected. This dual approach could transform prognosis and survival for thousands of men worldwide.

In conclusion, the discovery of tumor-indicating morphological changes in benign prostate biopsies through AI signals a new frontier in oncological diagnostics. It merges cutting-edge quantitative microscopy, sophisticated computational analysis, and clinical expertise to reveal the invisible signatures of cancer at its nascent stage. As this technology matures and integrates into healthcare workflows, it may redefine early cancer detection, enabling timely and targeted interventions that save lives.

Subject of Research: Human tissue samples
Article Title: Discovery of tumour indicating morphological changes in benign prostate biopsies through AI
News Publication Date: 21-Aug-2025
Web References: http://dx.doi.org/10.1038/s41598-025-15105-6
Image Credits: Mikael Wallerstedt
Keywords: Prostate cancer, Artificial intelligence, Histopathology, Digital microscopy, Tissue imaging, Early cancer detection, Quantitative morphology, AI diagnostics

The study led by Dr. Anqi Lin presents an in-depth evaluation of three state-of-the-art GenAI frameworks: GPT-4o, Claude-3.5-Sonnet, and Gemini-1.5-Pro. These models were trained and tested on an extensive data set comprising 310 diagnostic slides sourced from The Cancer Genome Atlas (TCGA) along with another 182 slides from various independent medical institutions. The focus was particularly on the ability of these AI systems to identify subtle pathological cancer patterns and accurately grade tumors, an endeavor generally fraught with interpretative variability among human experts. Remarkably, the results revealed that GenAI could achieve consistent, reproducible accuracy levels, signaling a breakthrough for digital pathology.

Among the trio, Claude-3.5-Sonnet surfaced as a frontrunner, reaching an average accuracy of 82.3% in differentiating cancer grades. Notably, its performance remained steadfast across repeated trials on identical slide sets, a significant measure of reliability in clinical contexts. This consistency addresses a critical hurdle in conventional pathology, where inter-observer variability poses persistent challenges, often affecting treatment decisions and patient prognoses. By providing uniform assessments, this GenAI model offers an indispensable tool for standardizing cancer grading at scale.

Yet, the implications of this work extend far beyond grading. The researchers engineered a prognostic model that synthesizes GenAI-extracted pathological features with patients’ clinical data, enabling predictive insights into disease progression and survival outcomes. This hybrid model encapsulates 11 distinct histological characteristics alongside 4 crucial clinical variables, collectively rendering a robust, mathematically grounded risk stratification framework. Such an integrative approach harnesses the strengths of AI and clinical medicine synergistically, potentially transforming personalized patient management.

One transformative advantage detailed in the study is the AI system’s efficiency in quantifying histological attributes such as tumor necrosis, cellular architecture, and inflammatory infiltrates with exact numerical percentages. This contrasts starkly with the traditional qualitative or semi-quantitative descriptions typically employed by pathologists. The transition from subjective observation to objective measurement not only streamlines workflows but also facilitates precise monitoring of disease progression or treatment response over time — a leap forward for evidence-based oncology.

The research team highlights the enormous potential of GenAI-assisted pathology especially in resource-limited settings. Global disparities in access to experienced pathologists frequently hinder timely diagnosis and treatment plans, magnifying cancer mortality in underserved regions. Deploying GenAI models capable of delivering high-fidelity diagnostic support on digital slide imagery could democratize access to expert-level pathology consultation worldwide, overcoming geographical and infrastructural barriers that impede cancer care equity.

Furthermore, the adoption of GenAI can significantly mitigate the long-standing problem of inter-observer variability. The study underscores how even leading pathologists can differ considerably when evaluating nuanced histological patterns, leading to inconsistent diagnoses. In contrast, AI-powered evaluations maintain unwavering consistency, reinforcing clinical confidence and reproducibility. This feature is particularly vital when assessing complex tumor heterogeneity or subtle morphological distinctions that influence grade assignment and prognosis.

Delving into the broader scientific implications, the AI models demonstrated the capability to concurrently analyze multiple histological features, uncovering prognostic factors previously underappreciated or overlooked. Among these, interstitial fibrosis, papillary pattern formations, and lymphocytic infiltration stood out as the most significant variables correlated with patient outcomes. The systematic, high-throughput quantification of such features, typically impractical via manual methods, paves the way for novel biomarker discovery and a deeper pathobiological understanding of lung adenocarcinoma.

This integrative GenAI methodology thus not only improves diagnostic accuracy and prognostication but also holds the promise to reshape therapeutic strategies. By elucidating intricate pathological signatures linked to disease aggressiveness and treatment response, clinicians could tailor interventions more precisely, advancing the frontier of personalized oncology. The capability to extract explainable features ensures that AI outputs remain interpretable, fostering trust and facilitating seamless integration into clinical workflows.

The study also addresses the technological robustness of the GenAI architectures used. Each model incorporates sophisticated natural language processing and image analysis techniques, enabling them to interpret complex tissue morphology from digital pathology slides. This dual capability underscores the evolving role of AI as a bridge between visual medical data and clinical reasoning, augmenting human intellect with computational power. The deployment of these models in real-world settings will require ongoing optimization and validation, but the foundational success reported here provides a strong impetus for rapid clinical adoption.

Importantly, the research team emphasizes ethical transparency and the absence of conflicts of interest, underscoring a commitment to unbiased scientific inquiry. Their pioneering work exemplifies how open collaboration between medical experts and AI technologists can generate impactful solutions without commercial bias, an essential factor in maintaining integrity as AI becomes increasingly entrenched in healthcare.

In summary, this landmark investigation heralds a new era where generative artificial intelligence empowers pathologists by enhancing diagnostic precision, reducing workload, and enabling comprehensive prognostic insights in lung adenocarcinoma. By harnessing the synergy of AI and clinical expertise, the study not only advances cancer diagnostics but also lays the groundwork for more equitable, consistent, and data-driven cancer care worldwide. As these GenAI models continue to mature and integrate seamlessly with medical practices, they promise to redefine standards, delivering faster, smarter, and more personalized oncology diagnostics on a global scale.

Subject of Research: People

Article Title: Evaluating generative AI models for explainable pathological feature extraction in lung adenocarcinoma: grading assessment and prognostic model construction

Web References:
http://dx.doi.org/10.1097/JS9.0000000000002507

Image Credits: Junyi Shen et al.

Keywords: Cancer, Internal medicine